Objectives To evaluate the feasibility, safety and efficacy of the min- diameter half and two convolutionsatria steel-wire that is used in improving percutaneous balloon mitralvalvuloplasy (PBMV)
Methods All patients received warfarin tabella every day for more than 3 months, underwent PBMV with the min-diameter half and two convolutions atria steel-wire and single balloonInoue technique after low dosage urokinase intravenous drip and Low Molecular Heparin injectio hypodermica every day for 5 days to observe the changes of haemodynamics and mitralvalve orifice area after PBMV. Following-up pulmonary arterial pressure inner diameter of left atrium complication as systematic thromboembolism
Results The achievement ratio was 98.9%. After PBMV, mean left atrial pressure (LAPm) and mean mitrial valve pressure gradient (MVPG) decreased from (28.5 ± 3.2) mmHg and (16.8 ± 3.8) mmHg to (10.3 ± 2.1) mmHg (P < 0.05) and (3.4 ± 2.8) mmHg (P < 0.01) respectively; Mitral valve orificearea (MVA) increased from (0.86 ± 0.26) cm2 to (1.67 ± 0.34) cm2 (P < 0.01). 6 months after PBMV Left atrial diameter (LAD) decreased from (65.30 ± 3.4) mm to (46.5 ± 4.3) mm (P > 0.05); Pulmonary pressure (PP) decreased from (63.8 ± 12.3) mmHg to (31.5 ± 12.7) mmHg (p < 0.05). 46 patients of heart function (NYHA) II to heart function I in 52 patients, 8 patients of heart function (NYHA) IIIto heart function II in 11 patients. No systemic thromboembolism occurred during PBMV and following-up.
Conclusions PBMV on patients after sufficient anticoagulation and thrombolysis combine the min- diameter half and two convolutions atria steel-wire that is used in improving single balloon Inoue technique is safe, feasible and effective.